In-vitro Colorectal Cancer Screening Tests Market

Market Overview:

The global in-vitro colorectal cancer screening tests market size reached US$ 943 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,352 Million by 2028, exhibiting a growth rate (CAGR) of 5.8% during 2023-2028.

In-vitro colorectal cancer screening tests are diagnostic procedures performed to detect adenomas, polyps and symptoms of colorectal cancer. Colorectal cancer refers to a medical condition that is characterized by the abnormal growth of cells in the large intestine, colon and rectum. Fecal occult blood (FOB), lateral flow immuno, transferrin assays, methylated gene, biomarker and guaiac FOB stool test are some of the commonly performed screening tests. In-vitro colorectal cancer screening tests involve the use of cameras that capture images of the digestive tract and transfers them to the recorder tied to the waist of the patient. They are minimally invasive and can aid in timely detection of cancer. As a result, in-vitro colorectal cancer screening tests are widely performed across clinics, hospitals and diagnostics laboratories. 

In-Vitro Colorectal Cancer Screening Tests Market Trends:

The increasing prevalence of colorectal cancer among the masses is one of the key factors driving the growth of the market. Moreover, rising awareness regarding the benefits of early detection and timely treatment of cancer is positively impacting the market growth. Various technological advancements, such as the integration of genetic testing in cancer screening tests, are providing a thrust to the market growth. These tests aid in early detection, developing treatment plans, preventing the spread of cancerous cells and minimizing the risks of developing associated disorders. In line with this, the increasing preference for minimally invasive (MI) diagnostic procedures to detect colorectal cancer is favoring the market growth. Other factors, including rising geriatric populations, which is more susceptible to such ailments and significant improvements in the healthcare industry, along with the implementation of various government initiatives mandating cancer screening tests, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global In-vitro colorectal cancer screening tests market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, imaging type and end user.

Breakup by Product:

• Fecal Occult Blood Tests

• Guaiac FOB Stool Test
• Immuno-FOB Agglutination Test
• Lateral Flow Immuno-FOB Test
• Immuno-FOB ELISA Test

• Biomarker Tests

• Tumor M2-PK Stool Test
• Transferrin Assays

• CRC DNA Screening Tests

• Methylated Gene Testing
• Panel DNA Tests 
   

Breakup by Imaging Type:

• Colonoscopy
• Proctoscopy
• CT Scan
• Ultrasound
• MRI
• PET Scan
   

Breakup by End User:

• Hospitals
• Clinics
• Diagnostic Laboratories
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG and Sysmex Corporation.

Report Coverage: